Results for tag: "Vorapaxar"

Vorapaxar is a novel antithrombotic drug used in the treatment of cardiovascular diseases. It is a protease-activated receptor-1 (PAR-1) antagonist, which works by blocking the activity of thrombin, a protein involved in the formation of blood clots. Vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is also used to reduce the risk of stroke in patients with a history of stroke or transient ischemic attack (TIA). The Vorapaxar market is a rapidly growing segment of the cardiovascular drugs market. It is expected to benefit from the increasing prevalence of cardiovascular diseases, as well as the growing demand for novel treatments. The market is also expected to benefit from the increasing focus on patient safety and the development of new technologies. Some of the major companies in the Vorapaxar market include Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Sanofi, and AstraZeneca plc. Show Less Read more